Clinical immunology
Recombinant human interleukin receptor antagonist influences serum chemokines in patients with rheumatoid arthritis
,
 
,
 
 
 
More details
Hide details
 
Submission date: 2014-04-07
 
 
Acceptance date: 2014-05-06
 
 
Publication date: 2014-06-27
 
 
Cent Eur J Immunol 2014;39(2):170-173
 
KEYWORDS
ABSTRACT
Objective: To investigate the serum expressions of chemokines CCL2 and CCL3 in patients with rheumatoid arthritis (RA) who were treated with recombinant human interleukin 1 (IL-1) receptor antagonist (IL-1Ra).
Material and methods: Serum CCL2 and CCL3 were determined using an enzyme-linked immunosorbent assay in 54 active RA patients before and after treatment with IL-1Ra or a placebo, as well as 36 healthy controls.
Results: Compared with the healthy controls, all the 54 RA patients exhibited higher serum CCL2 and CCL3 before and after treatment (p < 0.05). However, patients who had a good response to IL-1Ra treatment had significantly lower mean changes in the serum CCL2 and CCL3 levels from baseline to the last injection than IL-1Ra non-responders (p < 0.01).
Conclusions: CCL2 and CCL3 may be useful efficacy markers of IL-1Ra treatment.
eISSN:1644-4124
ISSN:1426-3912
Journals System - logo
Scroll to top